PMID- 29697209
OWN - NLM
STAT- MEDLINE
DCOM- 20191206
LR  - 20191217
IS  - 1757-5672 (Electronic)
IS  - 1757-5664 (Linking)
VI  - 11
IP  - 2
DP  - 2019 Apr
TI  - Efficacy and safety of mirabegron, a beta(3) -adrenoceptor agonist, in patients with 
      detrusor hyperactivity and impaired contractility.
PG  - O93-O97
LID - 10.1111/luts.12224 [doi]
AB  - OBJECTIVE: We examined the efficacy and safety of mirabegron in elderly patients 
      with urodynamic detrusor hyperactivity with impaired contractility (DHIC). 
      METHODS: Patients diagnosed with DHIC received daily dose of mirabegron (25mg). 
      Subjective symptom scores, uroflowmetry data, and adverse events (AEs) were 
      recorded for all patients at baseline and after 1, 3, and 6 months treatment. 
      Comparisons were made for each patient individually and between patients with 
      detrusor overactivity (DO). RESULTS: Of the 65 patients enrolled in the study, 25 
      had DHIC and 40 had DO (mean [+/- SD] age 79.3 +/- 9.6 and 75.6 +/- 10.7 years, 
      respectively). At the 6-month follow-up, significant (P < .05) improvement was 
      seen compared with baseline in both the DHIC and DO groups in terms of OAB 
      symptom scores (4.72 +/- 3.05 vs. 6.88 +/- 4.06 and 4.50 +/- 2.99 vs. 6.70 +/- 3.60, 
      respectively), urgency severity score (1.90 +/- 2.00 vs. 3.35 +/- 1.13 and 
      1.58 +/- 1.93 vs. 3.00 +/- 1.65, respectively), and global response assessment 
      (1.80 +/- 1.41 and 1.73 +/- 1.34, respectively). In the DHIC group, post-void 
      residual (PVR) volume decreased from 153 +/- 52.7 mL at baseline to 85.8 +/- 90.1 mL 
      at 6th month (P < .05) and voiding efficiency improved from 40.0 +/- 20.7% to 
      62.6 +/- 28.3% (P < .05). Common AEs included dry mouth and dizziness, yet 16% of 
      DHIC patients developed PVR >180 mL. CONCLUSION: Mirabegron was an effective 
      treatment option in elderly patients with urodynamic DO and DHIC in the present 
      study. The AEs reported were mild and infrequent.
CI  - (c) 2018 John Wiley & Sons Australia, Ltd.
FAU - Lee, Cheng-Ling
AU  - Lee CL
AUID- ORCID: 0000-0002-8692-2895
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AUID- ORCID: 0000-0001-7165-4771
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20180426
PL  - Australia
TA  - Low Urin Tract Symptoms
JT  - Lower urinary tract symptoms
JID - 101506777
RN  - 0 (Acetanilides)
RN  - 0 (Adrenergic beta-3 Receptor Agonists)
RN  - 0 (Thiazoles)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
MH  - Acetanilides/adverse effects/*therapeutic use
MH  - Adrenergic beta-3 Receptor Agonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Thiazoles/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy
MH  - Urodynamics/drug effects
OTO - NOTNLM
OT  - detrusor hyperactivity with impaired contractility
OT  - detrusor overactivity
OT  - efficacy
OT  - mirabegron
OT  - overactive bladder
OT  - safety
EDAT- 2018/04/27 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/04/27 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2018/03/12 00:00 [revised]
PHST- 2018/03/15 00:00 [accepted]
PHST- 2018/04/27 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2018/04/27 06:00 [entrez]
AID - 10.1111/luts.12224 [doi]
PST - ppublish
SO  - Low Urin Tract Symptoms. 2019 Apr;11(2):O93-O97. doi: 10.1111/luts.12224. Epub 
      2018 Apr 26.